Summer Sale

50% off Premium Yearly

00days
00hrs
00mins
00secs
HMP.TO 0.01SPGP 1.715ZUQ.TO 1.27NVDA 7.15GL 2.43MRK -3.06IEMG 1.96GEV 34.91
Patheon (PTI.TO)

Patheon (PTI.TO)

0.00
-0.00 (0.00%)
6 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
PAST TOP PICK

Patheon(PTI.TO)

Jan 26, 2005
(A Top Pick Nov 16/04. Up 14%.) Thinks it will go to at least the top of the trading range of $16. The times are right for the group.
Photo of Bill CarriganBill Carrigan
Owned
Unlock Rating
$10.12

Stock price when the opinion was issued

biotechnologypharmaceutical
SELL

Patheon(PTI.TO)

Jan 26, 2005
Would sell into this strength. An extremely tough business. It's characterized by rapid turnover of products, capital intensive and very fleeting profitability. Fully valued. Legal issues with management that has to be worked through.
Photo of Danny TomkaDanny Tomka
No
Unlock Rating
$10.12

Stock price when the opinion was issued

biotechnologypharmaceutical
BUY

Patheon(PTI.TO)

Jan 17, 2005
Believes in the long term management. Just made an acquisition in Puerto Rico which will be good.
Photo of David BaskinDavid Baskin
Owned
Unlock Rating
$10.08

Stock price when the opinion was issued

biotechnologypharmaceutical
TOP PICK

Patheon(PTI.TO)

Jan 14, 2005
What will be emerging over the next decade is more health care and cheaper. Attractive price. A good consevative way to participate in a growth sector.
Photo of Fred SturmFred Sturm
Owned
Unlock Rating
$9.91

Stock price when the opinion was issued

biotechnologypharmaceutical
DON'T BUY

Patheon(PTI.TO)

Jan 12, 2005
Year-end selling took place and there is a rally coming out of year end. Doesn't meet his tests.
Photo of David BurrowsDavid Burrows
No
Unlock Rating
$10.01

Stock price when the opinion was issued

biotechnologypharmaceutical
TOP PICK

Patheon(PTI.TO)

Jan 06, 2005
Trading at a very cheap multiple at about 14 X versus its historical multiple of 20 X earnings. The last 3 quarters have started to see the earnings ramp up. Margins are better too. Also likes their Peurto Rico acquisition which can be very accretive to them.
Photo of Werner MuehelemannWerner Muehelemann
Owned
Unlock Rating
$8.51

Stock price when the opinion was issued

biotechnologypharmaceutical
DON'T BUY

Patheon(PTI.TO)

Nov 29, 2004
Has had a lot of promise, but has never come through. Has made a lot of acquisitions and taken on a lot of debt. Earnings have not come through the way they should have.
Photo of Norman LevineNorman Levine
No
Unlock Rating
$9.00

Stock price when the opinion was issued

biotechnologypharmaceutical
TOP PICK

Patheon(PTI.TO)

Nov 26, 2004
(A Top Pick Sept 14/04. Up 4%.) Has been into long term support this fall. Likes the sector.
Photo of Bill CarriganBill Carrigan
Owned
Unlock Rating
$8.97

Stock price when the opinion was issued

biotechnologypharmaceutical
TOP PICK

Patheon(PTI.TO)

Nov 26, 2004
Feels that pharmaceutical companies are under a lot of pressure and have to become more efficient in manufacturing and increasing outsourcing. Likes the acquisition. Very profitable plants. Will generate surplus cash.
Photo of Jonathen Wellum, B. Comm, B. ScJonathen Wellum, B. Comm, B. Sc
No
Unlock Rating
$8.97

Stock price when the opinion was issued

biotechnologypharmaceutical
HOLD

Patheon(PTI.TO)

Nov 22, 2004
Seems like they have one bad situation after another. Now have an issue with the OSC. Still believes the story. Very good management. Very cheap.
Photo of David BaskinDavid Baskin
Owned
Unlock Rating
$7.65

Stock price when the opinion was issued

biotechnologypharmaceutical
DON'T BUY

Patheon(PTI.TO)

Nov 18, 2004
Once confusion starts, it never seems to go away, especially in this unforgiving market.
Photo of Bill CarriganBill Carrigan
No
Unlock Rating
$7.71

Stock price when the opinion was issued

biotechnologypharmaceutical
SELL

Patheon(PTI.TO)

Nov 09, 2004
OSC is conducting a probe re insider trading. Really haven't delivered on their promises. A very difficult business. Capital intensive.
Photo of Danny TomkaDanny Tomka
No
Unlock Rating
$8.60

Stock price when the opinion was issued

biotechnologypharmaceutical
WAIT

Patheon(PTI.TO)

Oct 26, 2004
Feels the bottom will be about $8.20 as long as there is no other cockroaches. Could drop further with tax loss selling in Nov/Dec.
Photo of Brian Acker, CABrian Acker, CAUnlock Rating
$8.52

Stock price when the opinion was issued

biotechnologypharmaceutical
BUY

Patheon(PTI.TO)

Oct 21, 2004
One of the better manufacturers of drugs. Had a stumble this last year as a drug being manufactured in the UK reached the end of its product cycle. Has positive earnings. Not a low PE. Prospects are quite good.
Photo of Michael SprungMichael Sprung
Owned
Unlock Rating
$8.90

Stock price when the opinion was issued

biotechnologypharmaceutical
BUY

Patheon(PTI.TO)

Sep 28, 2004
Well managed company. Has had some problems with a plant in the UK, but this is getting cleared up. Profitable.
Photo of Michael SprungMichael Sprung
Owned
Unlock Rating
$9.13

Stock price when the opinion was issued

biotechnologypharmaceutical
Showing 46 to 60 of 194 entries
The ultimate 360° Tracker Your financial life in one place, automatically

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

EPD -0.47$36.78
ET -0.025$19.045
MAIR 0$
RKLB 6.095$108.485
SESG-O 0$

Today's Top Picks

HMP.TO 0.01$9.76
SPGP 1.715$122.105
ZUQ.TO 1.27$108.74
NVDA 7.15$212.34
GL 2.43$169.19

Popular Articles

Latest Sell Signals

PRGO -0.14$10.85
CBRS 0$
HAWK 0$
AVEX 0$
SWMR 0$

Most Recent Experts

Jim Cramer - Mad Money

Jim Cramer - Mad Money

CNBC

Richard Orrell

Richard Orrell

RN Croft Financial Group

Stockchase Insights

Stockchase Insights

5i Research

The Panic-Proof Portfolio (Stockchase Research)

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Stan Wong

Stan Wong

Private Wealth Management, ScotiaMcleod

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica